ArticleNature communications2020
Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 101 citations in OpenAlex.
- Trial
- PredictedInternational journal of molecular sciences · 2026Article
- Pre-Existing Heterogeneity Predicts Rare Proteostasis-Stress Programs Across Diverse Perturbations.Biology · 2026Article
- Heterogeneous, population-level drug-tolerant persisters exhibit ion-channel remodeling and ferroptosis susceptibility.bioRxiv : the preprint server for biology · 2026Article
- Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.Nature communications · 2026Article
- The ubiquitin ligase KLHL6 drives resistance to CD8Nature · 2026Article
- DECODE: deep learning-based common deconvolution framework for various omics data.Nature methods · 2026Article
- Proteomics in Antitumor Drug Target Discovery, Toxicity, Resistance, and Precision Oncology.Drug design, development and therapy · 2026Review
- Transforming microfluidics for single-cell analysis with robotics and artificial intelligence.Lab on a chip · 2025Review
- Therapy-Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance.Journal of hematology & oncology · 2025Review
- Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition.Cell systems · 2025Article
- Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure.HemaSphere · 2025Article
- Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity.Cancer cell · 2025Article
- Review
- Purinergic CaCancers · 2024Article
- scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network.Cell reports. Medicine · 2024Article
- Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.Journal of clinical medicine · 2024Article
- Stem-cell states converge in multistage cutaneous squamous cell carcinoma development.Science (New York, N.Y.) · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Yapeng Su *Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.ORCID http://orcid.org/0000-0002-6305-8467
Melissa E Ko *Cancer Biology Program, Stanford University School of Medicine, Stanford, California, USA.
Hanjun ChengInstitute for Systems Biology, Seattle, Washington, USA.
Ronghui ZhuDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
Min XueDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.
Jessica WangDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.ORCID http://orcid.org/0000-0003-1421-4969
Jihoon W LeeDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.ORCID http://orcid.org/0000-0002-6749-5111
Luke FrankiwDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
Alexander XuInstitute for Systems Biology, Seattle, Washington, USA.
Stephanie WongDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
Lidia RobertDepartment of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Kaitlyn TakataDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.ORCID http://orcid.org/0000-0003-4864-9741
Dan YuanInstitute for Systems Biology, Seattle, Washington, USA.
Yue LuInstitute for Systems Biology, Seattle, Washington, USA.
Sui HuangInstitute for Systems Biology, Seattle, Washington, USA.
Antoni RibasDepartment of Medicine, University of California, Los Angeles, Los Angeles, California, USA.ORCID http://orcid.org/0000-0003-3669-8458
Raphael LevineDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, USA.
Garry P NolanDepartment of Microbiology and Immunology, Stanford University, Stanford, California, USA.
Wei WeiInstitute for Systems Biology, Seattle, Washington, USA.ORCID http://orcid.org/0000-0002-1018-7708
Sylvia K PlevritisDepartment of Radiology, Stanford University, Stanford, California, USA.
Guideng LiCenter of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lgd@ism.cams.cn.ORCID http://orcid.org/0000-0003-0840-7262
David BaltimoreDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA. baltimo@caltech.edu.ORCID http://orcid.org/0000-0001-8723-8190
James R HeathDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA. jheath@systemsbiology.org.ORCID http://orcid.org/0000-0001-5356-4385
California Institute of Technology · USInstitute for Systems Biology · USStanford University · USUniversity of California, Los Angeles · USChinese Academy of Medical Sciences & Peking Union Medical College · CNHebrew University of Jerusalem · ILUniversity of California, Riverside · US
Funding
University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MRepurposing of cancer therapeutics for treatment of patients with COVID-19 diseaseU54CA199090 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2015 to 2020
$11.4MSpatial-Genomic Integrative Multi-Species Analysis of Lymph Node MetastasisU54CA209971 · NCI · STANFORD UNIVERSITY · PI NOLAN, GARRY P, PLEVRITIS, SYLVIA KATINA · 2016 to 2021
$11.0MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DRY, SARAH M. · 2013 to 2017
$8.4MSteady states and cellular transitions associated with carcinogenesis and tumorprogressionU01CA217655 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., WEI, WEI · 2017 to 2021
$3.9MIdentifying Survivors of HSP90 Inhibitor Treatment In Breast Cancer by Mass CytometryF99CA212231 · NCI · STANFORD UNIVERSITY · PI KO, MELISSA ELLEN · 2016 to 2017
$73kNCI NIH HHS F99 CA212231NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS R35 CA197633NCI NIH HHS U01 CA217655NCI NIH HHS U54 CA199090NCI NIH HHS U54 CA209971NIGMS NIH HHS T32 GM007266
Abstract
The determination of individual cell trajectories through a high-dimensional cell-state space is an outstanding challenge for understanding biological changes ranging from cellular differentiation to epigenetic responses of diseased cells upon drugging. We integrate experiments and theory to determine the trajectories that single BRAF
Indexed as
Drug ToleranceGenomicsSingle-Cell AnalysisCell Line, TumorGenes, ReporterGreen Fluorescent ProteinsHumansMelanomaMetabolomicsMicrophthalmia-Associated Transcription FactorModels, MolecularProteomicsProto-Oncogene Proteins B-rafReproducibility of ResultsGreen Fluorescent ProteinsMicrophthalmia-Associated Transcription FactorProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.